Core Viewpoint - As of January 20, 2026, the number of shareholders for Furuimei Medical (300049) is reported to be 22,242 [1] Company Information - Furuimei Medical has engaged with investors through an interactive platform, indicating a level of transparency and communication with its shareholder base [1] - The company is actively monitoring its shareholder count, which may reflect its growth and investor interest [1]

Core Viewpoint - The A-share market is experiencing volatility with a divergence between large-cap and small-cap stocks, indicating a cautious sentiment among investors as they prepare for the upcoming holiday season [4][7]. Market Performance - The Shanghai Composite Index showed a slight increase of 0.16%, while the overall market saw 1,801 stocks rise and 39 stocks hit the daily limit up, contrasting with 36 stocks that hit the limit down [5][6]. - The trading volume in both markets reached 0.23 trillion yuan, reflecting an 8.92% increase, suggesting heightened market activity and significant trading disputes between bulls and bears [7]. Capital Flow - There is a notable outflow of institutional funds, while retail investors are showing a net inflow, indicating a shift in investment strategies. Institutions are moving away from high-valuation growth sectors like semiconductors and new energy, while increasing positions in defensive sectors such as liquor, precious metals, and high-dividend financial blue chips [8]. - Retail investors are generally adopting a wait-and-see approach, with many choosing to hold cash during the holiday, while a small number are following trends in liquor and precious metals [8]. Investor Sentiment - The sentiment among retail investors is cautious, with 36.45% increasing their positions, 18.28% reducing them, and 36.45% remaining inactive [13]. - A significant portion of investors (45.95%) reported being in a position of profit, while 37.16% are facing losses of up to 20% [19].

近期，资本市场交投氛围活跃，机构亦加快调研节奏，深入挖掘A股上市公司投资价值与潜在机会。 iFinD数据显示，2026年以来，已有670家上市公司接受了券商、公募等机构集中调研，合计调研次数达984次。其中，大金重工 （002487.SZ）、迈瑞医疗（300760.SZ）、超捷股份（301005.SZ）等企业成为机构调研的热门标的，参与调研的机构数量均超百家。 从行业与概念维度看，电子、机械设备等行业数量最多，脑机接口、商业航天等概念受追捧。 年内670家公司获机构调研 机构调研的广度与深度，直接反映出资本市场对不同行业的关注程度。根据iFinD数据，今年以来，已有670家上市公司接受了各类机构 的调研。从行业分布来看，电子、机械设备、医药生物等行业数量居前，均有60家以上，电力设备、计算机、汽车、基础化工等行业也 有超过40家企业接受调研。 近期，国家电网宣布，"十五五"时期固定资产投资预计达到4万亿元，较"十四五"时期投资增长40%。电力设备行业成为券商调研最热方 向之一，涵盖光伏、风电、电网设备、电池等板块。其中，大金重工今年以来获得209家机构调研，帝科股份（300842.SZ）接受123家 机构调研 ...

Core Viewpoint - The article highlights the positive performance of the ChiNext Medical ETF (国泰, 159377) amid supportive policies and a focus on innovation within the pharmaceutical and medical device sectors [1]. Group 1: Industry Policies and Innovations - Recent supportive policies are continuously emerging, leading to a recommendation for innovative drugs and medical devices along with their supply chains [1]. - The high demand for innovative drugs is noted, with a recommendation for Pharma companies that are expected to see a revaluation, as well as Biopharma/Biotech firms whose performance is entering a growth phase [1]. Group 2: Investment Opportunities - The report suggests investment in CXO and upstream pharmaceutical companies that benefit from innovation and a recovery in market conditions [1]. - In the medical device sector, companies that excel in engineering and have successful overseas expansions are recommended for investment [1]. Group 3: Future Catalysts - The report mentions that from 2026 onwards, there will be frequent catalysts in the medical device sector, with a focus on investment opportunities in overseas markets, brain-computer interfaces, and AI in healthcare [1]. Group 4: ETF Performance - The ChiNext Medical ETF (国泰, 159377) tracks the Innovation Medicine Index (创医药指数, 399275), which has a daily price fluctuation limit of 20% and includes listed companies involved in the research, production, and related services of innovative drugs [1].

| 成交量(万 | 成交金额(万 | 成交价格 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | | 股) | 元) | (元) | | | | | | | 方正证券股份有限公司湖北分 | 财通证券股份有限公司上海分 | | 100.00 | 2200.00 | 22.00 | | | | | | | 公司 | 公司 | （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨 询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保 证和承诺。 塞力医疗01月28日大宗交易平台共发生1笔成交，合计成交量100.00万股，成交金额2200.00万元。成交 价格平均为22.00元，相对今日收盘价折价5.54%。 01月28日塞力医疗大宗交易一览 ...

今日各行业资金流向 | 行业 | 日涨跌幅（%） | 资金流向（亿元） | 行业 | 日涨跌幅（%） | 资金流向（亿元） | | --- | --- | --- | --- | --- | --- | | 有色金属 | 5.92 | 106.92 | 社会服务 | -0.94 | -4.75 | | 通信 | 0.86 | 32.52 | 商贸零售 | -0.29 | -6.27 | | 建筑材料 | 2.18 | 17.21 | 非银金融 | -0.23 | -7.26 | | 基础化工 | 1.44 | 16.04 | 食品饮料 | -0.68 | -10.45 | | 银行 | -0.62 | 14.90 | 家用电器 | -1.47 | -19.16 | | 石油石化 | 3.54 | 13.74 | 建筑装饰 | -0.22 | -22.89 | | 煤炭 | 3.42 | 12.12 | 公用事业 | -0.39 | -23.69 | | 钢铁 | 2.16 | 8.87 | 计算机 | -1.02 | -31.71 | | 纺织服饰 | 1.46 | 7.85 | 传媒 | -1.77 | - ...

Core Viewpoint - Several A-share companies have announced optimistic earnings forecasts for 2025, with notable increases in net profits driven by rising prices in the non-ferrous metals sector [1][3]. Group 1: Company Earnings Forecasts - Ningbo Fubang (600768.SH) expects a net profit increase of 3099.59% to between 4379.43 million yuan and 5000 million yuan for 2025, attributed to rising silver prices and a significant gain from the sale of a stake in Ningbo Zhonghua Paper Industry [2][3]. - Yiqiu Resources (601388.SH) anticipates a net profit increase of 620% to 970%, with expected profits ranging from 13354.95 million yuan to 19854.95 million yuan, benefiting from lower raw material costs and increased sales prices due to global commodity price hikes [3][4]. - A total of 6 A-share companies are projected to have net profits increase by over 10 times in 2025, excluding ST and delisted stocks [1][2]. Group 2: Industry Insights - Among the companies that have released earnings forecasts, 253 are expected to see net profit growth of over 100% in 2025, with 123 companies turning losses into profits and 130 companies projecting profit increases [4]. - The electronics sector leads with 31 companies, followed by the pharmaceutical and biological sector with 29 companies, and the machinery equipment sector with 27 companies [4]. - The non-ferrous metals sector is highlighted, with 15 companies expecting to double their net profits in 2025, including notable firms like Zhaojin Gold (000506.SZ) and Ganfeng Lithium (002460.SZ) [4][5].

1月28日早盘，科创板权重股高开后震荡回调截至午间收盘，科创成长指数上涨0.1%，科创200指数下跌0.6%，科创50指数、科创100指数均下跌0.7%，科创 综指下跌0.8%。 该指数污 科创200ETF易方达 IFF = = 2 跟踪上证科创板200指数 该指数由科创板中市值偏小、流动 性较好的200只股票组成,聚焦小 市值"成长潜力"科创企业,电子、 医药生物、机械设备行业合计占比 近70%,其中电子行业占比较高 截至午间 该指数润 科创综指ETF易方达 低费率 跟踪上证科创板综合指数 性较好的100只股票组成,聚焦中 小科创企业,电子、电力设备、医 药生物、计算机行业合计占比超 75%,其中电子、电力设备行业占 比较高 截至午间 该指数: 每日经济新闻 该指数由科创板全市场证券组成, 全面覆盖大、中、小盘风格,聚焦 人工智能、半导体、新能源、创新 ...

2026.01. 28 本文字数：2709，阅读时长大约4.5分钟 作者 | 第一财经 周楠 当前正值上市公司年报预告披露期，不同于以往的绩优股抢先发布业绩，今年财报季里，一批亏损公司正在 密集"交卷"。 1 月 26 日 晚 间 ， 百 余 家 A 股 公 司 披 露 了 2025 年 业 绩 预 告 ， 多 家 亏 损 公 司 在 列 。 其 中 ， 大 禹 生 物 （920970.BJ）、ST英飞拓（002528.SZ）等续亏；二六三（002467.SZ）、恒基达鑫（002492.SZ）等首 亏。 另据Wind统计，截至1月26日，共计1165家A股公司已披露2025年业绩预告，业绩下滑的有709家，占比约 六成，当期预计亏损的有500多家。从行业来看，预亏幅度较大的企业扎堆房地产、建筑行业，涉及华夏幸 福（600340.SH）、绿地控股（600606.SH）等。华夏幸福预计去年亏损160亿元至240亿元，暂时成为"亏 损王"。 一些业绩"滑坡"的公司，遭遇投资者"用脚投票"。至纯科技（603690.SH）预计去年亏损3亿元至4.5亿元， 或出现上市以来的首次归母净利润亏损，消息披露后公司股票一度跌停。 ...

Core Viewpoint - The article highlights that listed companies are gradually overcoming operational difficulties and experiencing performance recovery, driven by initiatives such as "anti-involution," "quality improvement and efficiency enhancement," and "digital transformation" [1] Group 1: Performance Recovery - Nearly 1,250 companies that disclosed performance forecasts are expected to achieve a total net profit of over 173 billion yuan in 2025, with a nearly 100% increase compared to the previous year, marking the highest growth rate in the past five years [1] - The proactive disclosure of orders by listed companies aims to stabilize market expectations, boost investor confidence, and showcase growth potential, leading to a virtuous cycle of performance improvement and market confidence recovery [1] Group 2: Order-Driven Performance - Approximately 60 companies have reported increased orders, which are driving sustained growth or turning losses into profits, primarily in sectors such as electronics, machinery, power equipment, and biomedicine [3] - Among the companies benefiting from order increases, over half are expected to see net profit growth exceeding 100% in 2025, with notable examples including Tongda Co., which anticipates a net profit increase of over 610%, and Shengnuo Biotech, expecting over 280% growth [3][4] - Conversely, around 40 companies are facing revenue declines or losses due to reduced orders, with examples like Duolun Technology and Qinglong Pipe Industry reporting significant drops in revenue [4] Group 3: Market Performance of Order-Driven Companies - Companies driven by order growth have attracted significant market interest, with an average stock price increase of nearly 84% in 2025, outperforming the Shanghai Composite Index [6] - Specifically, companies with expected profit increases have shown an average stock price rise of over 90% in 2025, while loss-turning companies have seen average increases of over 75% [6] Group 4: Order Fulfillment and Future Growth - As of January 27, nearly 50 companies have reported sufficient orders, indicating a solid operational foundation for the year, covering industries such as electronics, defense, power equipment, and automotive [9] - Approximately 60% of these companies are projected to achieve net profit growth or significantly reduced losses in 2025, with 16 companies expected to maintain net profit growth exceeding 10% from 2025 to 2027 [9] - Companies like Shenghong Technology and Bai'ao Intelligent are expected to see substantial net profit growth in the coming years due to their strong order backlogs [9][10]